Boston Scientific Corporation $BSX Shares Purchased by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 9.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 320,038 shares of the medical equipment provider’s stock after buying an additional 28,961 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Boston Scientific were worth $13,659,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. Outfitters Financial LLC increased its stake in Boston Scientific by 0.5% during the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after purchasing an additional 110 shares during the period. Natural Investments LLC boosted its stake in shares of Boston Scientific by 2.9% in the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after purchasing an additional 112 shares during the period. Patton Fund Management Inc. grew its holdings in shares of Boston Scientific by 5.5% in the fourth quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider’s stock valued at $217,000 after purchasing an additional 118 shares in the last quarter. Bridgewater Advisors Inc. grew its holdings in shares of Boston Scientific by 1.2% in the fourth quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider’s stock valued at $921,000 after purchasing an additional 123 shares in the last quarter. Finally, CYBER HORNET ETFs LLC increased its stake in Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after buying an additional 132 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.1%

Shares of Boston Scientific stock opened at $49.35 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a market capitalization of $71.53 billion, a P/E ratio of 19.98, a P/E/G ratio of 1.08 and a beta of 0.56. The company has a 50 day moving average of $45.75 and a 200 day moving average of $60.73.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the firm posted $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

A number of research firms have issued reports on BSX. Citigroup reduced their target price on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Robert W. Baird set a $56.00 target price on Boston Scientific in a report on Thursday, July 30th. Finally, Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Insider Activity

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 204,322 shares of company stock worth $9,939,221. 0.34% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.